Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Healios K.K.
Plus deals involving BioLineRx/GloriaBio, Healios/Athersys, Aurobindo/Hilleman, Lupin/Menarini, GC Biopharma/Immetas, CanariaBio, Specialised Therapeutics, TaiGen/Y.S.P., Nippon/Kayaku/Adlai Nortye, WuXi/PharmaEssentia, Evommune/Maruho and Ono/Adimab.
Dr Toichi Takenaka, the first winner of the Lifetime Achievement Award in the inaugural Pharma Intelligence Awards Japan earlier this year, talks to Scrip about his journey from researcher to CEO and today as a mentor for Japanese bioventures. Starting his career in an “empty lab” in the 1960s motivated him to pursue a string of collaborations with universities in Japan and on to the discovery of four successful drugs.
Rona hopes technology acquired from Sanofi will enhance its RNA capabilities in liver and non-liver indications. NeuroFront gets Greater China and Singapore rights to Novaremed’s neuropathic pain drug.
A missed primary endpoint in new top-line results from a Japanese trial with the stem cell therapy for stroke MultiStem hits Athersys and Japanese partner hard, casting a shadow over ongoing studies.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
- Healios Riken, SighRegen K.K.
- Healios N.A. Inc.
- Organoid Neogenesis Laboratory Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.